Travere Therapeutics Inc (TVTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Travere Therapeutics Inc (TVTX) has a cash flow conversion efficiency ratio of -0.409x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.37 Million) by net assets ($98.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Travere Therapeutics Inc worth for the company's overall valuation and market capitalisation.
Travere Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Travere Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Travere Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Travere Therapeutics Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Travere Therapeutics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jb Financial
KO:175330
|
-0.126x |
|
Infore Environment Technology Group Co Ltd
SHE:000967
|
-0.009x |
|
CCOOP Group Co Ltd
SHE:000564
|
-0.008x |
|
Bohai Leasing Co Ltd
SHE:000415
|
0.138x |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
-0.038x |
|
Aris Mining Corporation
TO:ARIS
|
0.033x |
|
Cosan SA ADR
NYSE:CSAN
|
0.029x |
|
VEON Ltd
NASDAQ:VEON
|
0.196x |
Annual Cash Flow Conversion Efficiency for Travere Therapeutics Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of Travere Therapeutics Inc from 2010 to 2025. View Travere Therapeutics Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $114.83 Million | $37.78 Million | 0.329x | +108.19% |
| 2024-12-31 | $59.08 Million | $-237.47 Million | -4.020x | -188.27% |
| 2023-12-31 | $200.81 Million | $-280.02 Million | -1.394x | +67.92% |
| 2022-12-31 | $42.85 Million | $-186.29 Million | -4.347x | -8779.16% |
| 2021-12-31 | $302.11 Million | $-14.79 Million | -0.049x | +75.81% |
| 2020-12-31 | $211.21 Million | $-42.74 Million | -0.202x | +23.11% |
| 2019-12-31 | $221.20 Million | $-58.21 Million | -0.263x | -235.59% |
| 2018-12-31 | $318.25 Million | $-24.96 Million | -0.078x | -410.52% |
| 2017-12-31 | $293.13 Million | $7.40 Million | 0.025x | +587.00% |
| 2016-12-31 | $307.77 Million | $-1.60 Million | -0.005x | -180.79% |
| 2015-12-31 | $299.97 Million | $-554.00K | -0.002x | -100.15% |
| 2014-12-31 | $-37.25 Million | $-45.85 Million | 1.231x | +28.14% |
| 2013-12-31 | $-18.31 Million | $-17.59 Million | 0.961x | +19.61% |
| 2012-12-31 | $-3.41 Million | $-2.74 Million | 0.803x | +103283.92% |
| 2011-12-31 | $-63.08K | $-49.00 | 0.001x | -93.21% |
| 2010-12-31 | $-60.26K | $-689.00 | 0.011x | -- |
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola a… Read more